Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks ...

We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...

Regeneron (REGN) came out with quarterly earnings of $11.86 per share, beating the Zacks Consensus Estimate of $10.43 per share. This compares to earnings of $12.56 per share a year ago.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Compared to Q4 2024, Q1 2025 saw a decline in EYLEA net ... pressures and potential delays in key product approvals. Regeneron faced mixed results in Q1 2025 with challenges in its retinal ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

April 22 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially ...